Search
Back

Baricitinib

CAS 1187594-09-7
Baricitinib

General Information

Baricitinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Baricitinib is indicated for treating adults with moderate to severe rheumatoid arthritis who have not responded well enough to or could not tolerate at least one tumor necrosis factor antagonist.


About the API

Technology Synthetic
Therapeutic category Rheumatology
Available formulations Oral Solid
Regulations
  • Japan DMF
  • Korea DMF
  • US DMF

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.

For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.